Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy

(MedPage Today) -- Progression-free survival (PFS) improved in advanced HER2-mutant non-small cell lung cancer (NSCLC) when treatment started with trastuzumab deruxtecan (T-DXd; Enhertu) instead of pembrolizumab (Keytruda) and chemotherapy, a large...